BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 25357116)

  • 1. Diagnostic approach to eosinophilic renal neoplasms.
    Kryvenko ON; Jorda M; Argani P; Epstein JI
    Arch Pathol Lab Med; 2014 Nov; 138(11):1531-41. PubMed ID: 25357116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostic utility of immunohistochemistry in differential diagnosis of renal tumors with oncocytic features].
    Zhang W; Yu WJ; Chen YQ; Kang EH; Liu Y; Zhuang J; Jiang YX; Chu J; Li YJ
    Zhonghua Bing Li Xue Za Zhi; 2016 Oct; 45(10):692-697. PubMed ID: 27760610
    [No Abstract]   [Full Text] [Related]  

  • 3. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
    Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
    Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnostic utility of S100A1, GLUT-1 and Caveolin-1 in renal tumors with oncocytic features: a comparative study].
    Zhang W; Wang K; Yu W; Liu Y; Chu J; Jiang Y; Li Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Nov; 44(11):767-71. PubMed ID: 26888385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proximal CD13 Versus Distal GATA-3 Expression in Renal Neoplasia According to WHO 2016 Classification.
    Brunelli M; Erdini F; Cima L; Eccher A; Fioravanzo A; Gobbo S; Segala D; Ghimenton C; Mazzoleni G; Munari E; Carella R; Martignoni G
    Appl Immunohistochem Mol Morphol; 2018; 26(5):316-323. PubMed ID: 27556823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-evaluation of histological type by immunohistochemical and genetic study of transcription factors (TFE3 and TFEB) of VHL gene mutation-negative clear cell renal cell carcinoma and other special types of renal tumor.
    Kuroda N; Kawada C; Tamura K; Hiroi M; Hes O; Michal M; Wada Y; Inoue K; Ohara M; Mizuno K; Shuin T; Lee GH
    Med Mol Morphol; 2011 Mar; 44(1):46-51. PubMed ID: 21424937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
    Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
    Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic pitfall on the histological spectrum of adult-onset renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.
    Kuroda N; Katto K; Tanaka Y; Yamaguchi T; Inoue K; Ohara M; Mizuno K; Hes O; Michal M; Lee GH
    Med Mol Morphol; 2010 Jun; 43(2):86-90. PubMed ID: 20683695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights in the new WHO classification of adult renal tumors.
    Hes O; Michalová K; Pivovarčíková K
    Cesk Patol; 2022; 67(4):187-191. PubMed ID: 36513503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
    Trpkov K; Hes O; Agaimy A; Bonert M; Martinek P; Magi-Galluzzi C; Kristiansen G; Lüders C; Nesi G; Compérat E; Sibony M; Berney DM; Mehra R; Brimo F; Hartmann A; Husain A; Frizzell N; Hills K; Maclean F; Srinivasan B; Gill AJ
    Am J Surg Pathol; 2016 Jul; 40(7):865-75. PubMed ID: 26900816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
    Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
    J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases.
    He H; Trpkov K; Martinek P; Isikci OT; Maggi-Galuzzi C; Alaghehbandan R; Gill AJ; Tretiakova M; Lopez JI; Williamson SR; Montiel DP; Sperga M; Comperat E; Brimo F; Yilmaz A; Pivovarcikova K; Michalova K; Slouka D; Prochazkova K; Hora M; Bonert M; Michal M; Hes O
    Virchows Arch; 2018 Dec; 473(6):725-738. PubMed ID: 30232607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis.
    Yang B; Duan H; Cao W; Guo Y; Liu Y; Sun L; Zhang J; Sun Y; Ma Y
    Mod Pathol; 2019 Oct; 32(10):1521-1535. PubMed ID: 31175325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma.
    Hayes M; Peckova K; Martinek P; Hora M; Kalusova K; Straka L; Daum O; Kokoskova B; Rotterova P; Pivovarčikova K; Branzovsky J; Dubova M; Vesela P; Michal M; Hes O
    Virchows Arch; 2015 Mar; 466(3):313-22. PubMed ID: 25544614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
    Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
    Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
    Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
    Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
    Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
    [No Abstract]   [Full Text] [Related]  

  • 18. Emerging Entities in Renal Neoplasia.
    Mehra R; Smith SC; Divatia M; Amin MB
    Surg Pathol Clin; 2015 Dec; 8(4):623-56. PubMed ID: 26612218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms.
    Caliò A; Marletta S; Brunelli M; Pedron S; Portillo SC; Segala D; Bariani E; Gobbo S; Netto G; Martignoni G
    Virchows Arch; 2022 Dec; 481(6):877-891. PubMed ID: 35980471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Renal cell carcinoma with t(6;11)(p21.2;q13)/MALAT1-TFEB fusion: a clinical and pathological analysis].
    Xia Q; Shi S; Shen Q; Wei X; Wang X; Ma H; Lu Z; Zhou X; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2015 Dec; 44(12):895-9. PubMed ID: 26888508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.